Skip to main content

Table 1 The characteristics of the patients in derivation set and validation set

From: Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma

Variables Derivation set Validation set p value
N 348 158  
Age (years) 55.8 ± 9.5 54.7 ± 10.4 0.246
BMI (kg/m2) 24.3 ± 3.3 22.2 ± 2.5  < 0.001
Sex (Male, %) 250 (71.8) 102 (64.6) 0.099
HBsAg (%) 197 (56.6) 74 (46.8) 0.041
Hepatitis C (%) 19 (5.5) 4 (2.5) 0.143
Cirrhosis (%) 203 (58.3) 66 (41.8) 0.001
Tumor number (Multiple, %) 43 (12.4) 23 (14.6) 0.496
Capsule (Incomplete, %) 28 (8.0) 57 (36.1)  < 0.001
The largest nodule diameter (cm) 5.4 ± 3.1 6.5 ± 4.6 0.007
WBC (× 109/L) 6.04 ± 2.09 8.34 ± 4.09  < 0.001
Haemoglobin (g/L) 140.1 ± 15.9 124.7 ± 22.5  < 0.001
Platelet count (× 109/L) 182.7 ± 74.8 202.1 ± 99.8 0.03
MPV (fL) 14.5 ± 2.5 13.3 ± 2.1  < 0.001
PDW (%) 15.2 ± 2.3 13.2 ± 2.2  < 0.001
AST (U/L) 29 (22–43) 41 (26–77)  < 0.001
ALT (U/L) 30 (19–48) 56 (29–116)  < 0.001
γ-GGT (U/L) 65 (33–138) 96 (51–196)  < 0.001
Total bilirubin (μmol/L) 14.5 (11.2–18.2) 20.1 (14.3–37.1)  < 0.001
AFP (ng/mL) 6.08 (2.61–97.4) 6.23 (2.70–270.1) 0.818
CA19-9 (U/mL) 22.8 (11.3–50.5) 23.5 (12.2–59.4) 0.829
FIB-4 2.8 (1.7–4.7) 1.9 (1.1–3.0) 0.014
APRI 0.7 (0.4–1.4) 0.7 (0.3–1.2)  < 0.001
NLR 2.87 ± 1.76 4.03 ± 1.94  < 0.001
  1. Data are expressed as means (SD) or percentage. SD, standard deviation; BMI, body mass index; HBsAg, hepatitis B surface antigen; WBC, white blood cell count; MPV, mean platelet volume; PDW, platelet distribution width; AST, aspartate transaminase; ALT, alanine transaminase; γ-GGT, γ-glutamyl transferase; AFP, alphafetoprotein; CA19-9, carbohydrate antigen 19–9; APRI, aspartate aminotransferase/platelet ratio index; FIB-4, fibrosis-4; NLR, neutrophil-to-lymphocyte ratio. Bold indicates statistically significant values (P < 0.05)